Loading…
Omega Healthcare Investors, Inc.
🏹 Trader: 🎯 Near 52W High View all →
$13.6B
Market Cap
22.9
P/E
9.04
PEG
7.5%
ROCE
12.0%
ROE
0.78
D/E
60.3%
OPM
-8.0%
% from 52W High
56
α RS
🔍 OHI is showing a sector-leadership setup because Sector RRG has Health Care in the Leading quadrant with the trail still strengthening, it matches 2 of 37 tracked screener presets, and an ECS of 60.2 last quarter. Net: Broad signal stack, not a recommendation. ? RRG Conviction ECS
Sources
Health Care in Leading quadrant · Conviction 2/37 · ECS 60.2
⚖️ Compare 🔒 Generate Report 🔒 Research Packet 📚 Guides
🌏 Global Investor Returns
Currency-adjusted total returns for OHI including FX impact
🌏
Click 🌏 Returns tab to load data
📈 Price History
Ratio Health
Excellent
Good
Average
Poor
By Category
📊 Sector Averages
About

Omega Healthcare Investors, Inc. is a real estate investment trust that invests in the long-term healthcare industry, primarily in skilled nursing and assisted living facilities.

Key Ratios Snapshot
📈 Growth Pattern
📊 Quick Scorecard
Loading…
⭐ Superinvestors Holding OHI
View All Superinvestors →
Manager Shares Value % of Fund Period
Jim Simons Renaissance Technologies LLC 625.4K $27.4M 0.04% Mar 2026
Steve Cohen Point72 Asset Management 54.2K $2.4M 0.00% Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔒
Premium Feature
AI-generated 10-section company profile — business model, financials, strengths, risks & management quality
Upgrade to Premium
Already a member? Log in
📐
3-Statement Financial Model
Bear / Base / Bull projections · DCF fair value · Reverse-DCF
Open Model →
🎙 Management Tone Confident Specific → Stable 4 quarters Full tone analysis in Intelligence →
📊 MIXED Omega Healthcare Q1 AFFO $0.82, FAD $0.78, $480M CommuniCare sale
Revenue & Profitability
First-quarter 2026 revenue was $323 million (up from $277 million in Q1 2025). Net income was $159 million ($0.47 per share) versus $112 million ($0.33). Adjusted FFO was $260 million ($0.82 per share) and FAD was $247 million ($0.78 per share). Fixed charge coverage was 6.3x and leverage was 3.5x. Full-year AFFO guidance was narrowed to $3.19-$3.25 per share (midpoint $3.22).
Outlook
Management sees strong industry demand due to aging demographics and no net new SNF supply over the past decade. They note headwinds from Medicare Advantage denial rates and managed Medicaid issues, but applaud bipartisan legislation addressing these concerns. Occupancy is expected to increase over the next year or two.
Growth Drivers
Growth is driven by expanding the RIDEA platform in U.S. senior housing, acquiring SNFs at attractive yields, and growing the U.K. care home portfolio. The $480 million CommuniCare sale is expected to redeploy capital at approximately $0.03 annual AFFO/FAD accretion. Year-to-date investments total $326 million.
Balance Sheet & CapEx
Year-to-date, Omega completed $326 million in new investments. Q1 investments of $251 million included a 9.9% equity stake in Saber Healthcare, a $109 million Georgia SNF acquisition, and $10 million in Alabama senior housing RIDEA. The pipeline focuses on U.S. senior housing RIDEA deals targeting mid-teens IRRs.
Margins
Not discussed in detail. Margin indicators include a dividend payout ratio of 82% on AFFO and 86% on FAD, with fixed charge coverage of 6.3x and leverage of 3.5x.
Key Risks
Key risks include the Genesis bankruptcy process (DIP loan and term loan repayment), execution of the CommuniCare sale, and regulatory issues such as Medicare Advantage denial rates and managed Medicaid unwind in states like Indiana. Litigation risk from operator care issues was also discussed.
Generated by AI · Q1 2026 results · Not investment advice
🔒
Free Account Required

Create a free Finmagine account to access Finmagine™ Scorecard.

See how this company scores across 5 dimensions — Financial Health, Growth Prospects, Competitive Position, Management Quality, and Valuation — powered by 30+ computed ratios.

Create Free AccountLog In
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Ask AI.

Get 25 expert AI analysis templates — Business KPIs, Comprehensive, Forensic Governance, Peer Comparison, Risk-Reward, Full Research Report, IPO Decoder, Red Flag Detector, and more — ready to paste into ChatGPT, Claude, Gemini, or Perplexity.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Peer Comparison.

Compare this company side-by-side against its sector peers with financial metrics, ratio benchmarking, and relative performance across all key dimensions.

Upgrade to PremiumCreate Free Account
✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter
🔍
🔎 See cross-company document search → ?
📞 Earnings Call Transcripts (5)
Q2 2026 Q2 2026 2026-07-30
Q2 2026 saw strong revenue and net income growth, driven by asset sales and new investments, with leverage at historic lows and a raised AFFO guidance. Portfolio management remains proactive, with no major operator concerns and a robust pipeline in senior housing and U.K. care homes.
Q1 2026 Q1 2026 2026-04-29
Q1 2026 saw strong AFFO and FAD growth, driven by acquisitions and active portfolio management, with a robust investment pipeline and competitive market conditions. Asset sales and redeployment are expected to further boost earnings, while guidance was raised for the year.
Q4 2025 Q4 2025 2026-02-05
Q4 2025 saw strong revenue and earnings growth, driven by $1.1B in new investments and portfolio management. Guidance for 2026 projects AFFO of $3.15–$3.25 per share, with a robust pipeline and improved operator credit. Balance sheet strength and selective acquisitions position the company for continued growth.
Q3 2025 Q3 2025 2025-10-31
Q3 2025 saw strong revenue and earnings growth, with AFFO guidance raised to reflect 8% year-over-year growth. Strategic investments, including a major SABR joint venture, and robust portfolio performance support a positive outlook, while the balance sheet remains strong.
Q2 2025 Q2 2025 2025-08-01
Q2 2025 saw strong revenue and earnings growth, driven by acquisitions and portfolio management, with adjusted FFO of $0.77/share and FAD of $0.74/share. Guidance was raised, leverage hit a decade low, and major investments and legislative wins support a positive outlook.
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Catalyst Timeline.

Every result, order win, insider trade, ECS update, earnings-call, and SEC announcement for this company — in one chronological lane.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Full Report.

Read the complete Finmagine™ investment research report — comprehensive fundamental analysis, business model assessment, competitive positioning, and investment recommendation.

Upgrade to PremiumCreate Free Account

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯
Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.
📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

Financial Model
Projections are built from each company's audited annual financials (Income Statement, Balance Sheet, Cash Flow) over the last 5 fiscal years. Forward assumptions — revenue growth %, EBITDA margin, D&A (USD millions), interest expense, tax rate, and capex — are AI-generated using historical context and refreshed twice a year: after the December results season and after the September/Q4 results season.

DCF Valuation
Fair Value = Σ(FCFt / (1+WACC)t) + Terminal Value. Terminal Value uses the Gordon Growth Model: FCF5 × (1+g) / (WACC−g). Default WACC: 10% (US risk-free ~4.5%, equity risk premium ~5.5%). Default terminal growth: 3% (long-run US nominal GDP proxy).

CAGR Tracker
Expected 5-year CAGR = (DCF Fair Value / Current Price)1/5 − 1. Assumes fair value is reached in exactly 5 years — a mechanical estimate only.

Data Sources & Limitations
Financial statements sourced from public filings. Prices updated daily. Forward assumptions are AI-generated. All monetary values in USD millions. Non-US ADR companies may have currency conversion inaccuracies. Models are point-in-time and do not update intra-quarter or account for M&A, macro shocks, or extraordinary items.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.